+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Indication (Diabetic Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion), Product (Aflibercept, Bevacizumab, Brolucizumab), Type, End Use, Distribution Channel, Dosage Form - Global Forecast 2025-2030- Product Image
Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Indication (Diabetic Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion), Product (Aflibercept, Bevacizumab, Brolucizumab), Type, End Use, Distribution Channel, Dosage Form - Global Forecast 2025-2030- Product Image
New

Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Indication (Diabetic Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion), Product (Aflibercept, Bevacizumab, Brolucizumab), Type, End Use, Distribution Channel, Dosage Form - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6147462
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Understanding the critical role of monoclonal antibody anti-VEGF therapies in revolutionizing treatment approaches for retinal vascular diseases

Retinal vascular diseases such as wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion impose a profound clinical burden that has historically challenged ophthalmic care. The introduction of monoclonal antibody therapies targeting vascular endothelial growth factor (VEGF) represented a watershed moment, fundamentally shifting treatment paradigms from periodic laser photocoagulation to precision biologic interventions delivered via intravitreal injection. By neutralizing VEGF activity within the retinal microenvironment, these therapies have not only improved visual acuity outcomes but also reduced the risk of irreversible vision loss across diverse patient populations.


Over the past decade, iterative refinements in dosing schedules, administration techniques, and molecular engineering have further enhanced both efficacy and patient convenience. Real-world evidence underscores consistent gains in vision letters across clinical subgroups, while safety profiles continue to support broad adoption in clinical practice. As healthcare systems increasingly emphasize value-based care, the ability of these targeted biologics to deliver sustained therapeutic benefits with manageable treatment burdens positions them at the forefront of retinal disease management.


This executive summary synthesizes the latest industry trends, strategic imperatives, and actionable insights that will guide stakeholders through the evolving landscape of monoclonal antibody anti-VEGF ophthalmic therapies.

Exploring paradigm shifts driven by novel therapies and emerging technologies reshaping patient care and clinical outcomes in ophthalmic anti-VEGF treatment

The ophthalmic anti-VEGF landscape is experiencing a wave of transformative shifts driven by novel molecular entities, advanced delivery technologies, and integrated patient-centric models. Emerging agents with extended durability profiles are challenging conventional monthly injection regimens, offering the promise of reduced treatment burden and enhanced adherence. Concurrently, innovative sustained-release implants and refillable port delivery systems are progressing through late-stage clinical evaluation, foreshadowing a new era of long-acting ocular therapeutics.


Beyond molecular innovation, the integration of digital health platforms and remote imaging technologies is facilitating personalized dosing algorithms. By leveraging home-based optical coherence tomography and AI-driven analytics, clinicians can tailor injection intervals to real-time disease activity, optimizing visual outcomes while minimizing clinic visits. Regulatory agencies are responding with adaptive approval pathways and real-world data frameworks that accelerate market entry for differentiated therapies.


In tandem, the emergence of biosimilar competitors is reshaping competitive dynamics, prompting originator companies to enhance value propositions through bundled service offerings, patient support programs, and outcome-based contracting. These intersecting trends collectively underscore a landscape in constant evolution, where therapeutic innovation and patient engagement coalesce to redefine standards of care.

Assessing how impending 2025 United States tariff implementations are influencing cost structures supply chain strategies and competitive positioning

Trade policy developments slated for 2025 in the United States are set to influence cost structures and strategic positioning across the ophthalmic biologics value chain. Anticipated tariff adjustments on imported biologic raw materials and finished goods have prompted manufacturers to reevaluate sourcing strategies and consider regional manufacturing alternatives. By nearshoring critical production steps, organizations can mitigate exposure to tariff volatility and secure supply continuity for high-value monoclonal antibodies.


In response, leading developers are forging strategic alliances with contract manufacturing organizations in tariff-favored jurisdictions and reinvesting in domestic production capacity. These initiatives enable a more agile response to policy shifts while enhancing control over quality and lead times. Pricing teams are concurrently recalibrating commercial models to incorporate scenario planning for duty fluctuations, ensuring that end-user affordability remains aligned with provider reimbursement frameworks.


The interplay between trade regulations and commercialization strategies underscores the importance of a holistic supply chain architecture. Companies that proactively integrate tariff risk assessments into their operational planning will be better positioned to sustain margins, manage inventory levels, and maintain competitive access to critical anti-VEGF therapies.

Unveiling strategic insights across indication product type end use distribution channel and dosage form to inform targeted growth strategies

Segmentation analysis reveals distinct patterns in clinical adoption and service delivery. When evaluating monoclonal antibody anti-VEGF therapies by indication, diabetic macular edema and diabetic retinopathy cases benefit from protocols focused on reducing retinal thickness and improving vascular integrity, whereas retinal vein occlusion management prioritizes rapid edema resolution. In wet age-related macular degeneration, durable dosing intervals remain paramount to preserving central vision over extended periods.


Product differentiation further stratifies treatment pathways. Aflibercept’s fusion protein design offers high VEGF affinity and extended dosing intervals, while Bevacizumab, though used off-label, continues to be leveraged for its established safety profile and cost effectiveness. Brolucizumab’s high-concentration formulation addresses deep tissue penetration but necessitates vigilance around inflammatory events, and Ranibizumab’s robust clinical legacy underpins its continued presence in first-line regimens. Within this landscape, biosimilar entrants are challenging branded exclusivity, driving a competitive dialogue around pricing and clinical equivalence.


Settings of care vary according to procedural efficiency and infrastructure. Ambulatory surgical centers deliver streamlined injection workflows, hospital ophthalmology clinics offer comprehensive diagnostic services, and specialty eye hospitals provide multidisciplinary management for complex retinal cases. Distribution pathways reflect evolving access models, with hospital pharmacy inventories regulated by formulary committees, online pharmacy platforms expanding patient reach, and retail pharmacy networks supporting community-level dispensing. Finally, dosage form selection balances convenience and waste reduction: prefilled syringes minimize preparation time, whereas vials enable flexible dosing across patient cohorts.

Examining regional dynamics in the Americas Europe Middle East and Africa and Asia Pacific to uncover localization and adoption trends

The Americas region exhibits robust infrastructure for intravitreal injection protocols, supported by comprehensive reimbursement frameworks and a strong emphasis on value-based contracting. In North America, early adoption of extended-interval therapies has been facilitated by well-established payer pathways, while Latin American territories are navigating variable approval timelines and expanding patient access through public-private partnerships.


In Europe Middle East & Africa, centralized marketing authorizations within the European Union are complemented by localized pricing negotiations that shape patient affordability. The Middle Eastern markets demonstrate growing investments in specialty eye care centers and strategic collaborations with global developers, whereas African nations face infrastructure challenges that are being addressed through capacity-building programs and non-profit initiatives aimed at increasing screening and treatment access.


Asia-Pacific presents a diverse tapestry of market dynamics. Mature markets such as Japan and Australia leverage streamlined regulatory processes and integrated healthcare networks to adopt advanced therapies rapidly. In emerging economies, cost containment is driving accelerated biosimilar penetration and localized manufacturing initiatives, supported by government policies focused on enhancing domestic biopharmaceutical capabilities.

Delving into the strategies and portfolios of leading biopharma companies shaping the competitive landscape of ophthalmic anti-VEGF therapies

Leading biopharmaceutical companies are refining their portfolios to sustain leadership in the anti-VEGF domain. Originator firms are advancing next-generation molecules with optimized binding affinities and improved pharmacokinetics. Joint ventures with biotech innovators are accelerating the development of bispecific constructs that simultaneously target VEGF and complementary angiogenic pathways, thereby addressing refractory cases.


Major players are also investing heavily in device co-development, integrating ocular imaging platforms with therapeutic delivery systems to foster closed-loop management of retinal diseases. At the same time, biosimilar manufacturers are scaling capabilities to meet regulatory requirements for interchangeability, engaging in intellectual property negotiations and forging licensing agreements to expedite market entry.


Across the competitive spectrum, organizations that couple strategic R&D investments with agile manufacturing frameworks are emerging as frontrunners. Focused collaborations with academic institutions and patient advocacy groups further strengthen clinical insights and support tailored access programs, underlining a commitment to both innovation and patient-centricity.

Guiding industry leaders with actionable recommendations to accelerate innovation optimize access and reinforce resilience in anti-VEGF drug development

Accelerating innovation in anti-VEGF drug development requires a proactive emphasis on extended-release formulations that reduce injection frequency and enhance patient adherence. Companies should explore partnerships with device manufacturers to co-create novel delivery technologies and leverage real-world evidence initiatives early in the clinical lifecycle to bolster value-based contracting with payers.


Strengthening supply chain resilience is equally critical. Diversifying raw material suppliers, considering nearshore production hubs, and implementing dynamic tariff planning will mitigate the risk of policy-driven disruptions. Engaging regulatory agencies through adaptive review pathways and rolling submissions can further streamline approval processes, allowing for staggered launches across key jurisdictions.


Embracing digital health solutions-from remote monitoring tools to teleophthalmology platforms-can expand treatment reach in underserved areas and reinforce patient engagement. Adopting a balanced portfolio strategy that integrates both branded biologics and biosimilar launches will optimize lifecycle value and ensure sustained competitive differentiation.

Detailing a rigorous multi-source research methodology integrating primary interviews data triangulation and regulatory analysis to underpin the study findings

This study employed a mixed-method research design that began with an exhaustive review of scientific literature, clinical trial registries, and public regulatory records to construct a foundational understanding of anti-VEGF therapy advancements. Primary insights were then enriched through in-depth interviews with leading retinal specialists, pharmacologists, and policy experts, capturing firsthand perspectives on clinical challenges and adoption barriers.


Quantitative data was corroborated through triangulation, integrating intelligence from patent databases, supply chain analytics platforms, and proprietary trade records. This enabled a nuanced evaluation of tariff impacts, manufacturing capacities, and distribution efficiencies under various policy scenarios. Concurrently, regulatory landscapes across major geographies were mapped to assess approval timelines, pricing negotiations, and access programs.


Iterative validation rounds involved feedback loops with industry practitioners to confirm emerging trends and refine strategic imperatives. This rigorous methodology ensures that the study’s findings are both robust and actionable for stakeholders navigating the complex anti-VEGF therapy environment.

Concluding perspectives highlighting strategic imperatives and forward-looking takeaways for stakeholders navigating the anti-VEGF ophthalmic therapy arena

Monoclonal antibody therapies targeting VEGF remain integral to the management of retinal vascular diseases, but the competitive and regulatory landscape is evolving at an accelerated pace. Biosimilar competition, shifting reimbursement models, and evolving delivery technologies demand that stakeholders adopt a forward-looking posture to sustain market leadership.


Segmentation insights underscore the necessity of tailoring therapeutic approaches by indication, product design, setting of care, and dispensing channels. Regional analyses further reveal divergent adoption drivers, from reimbursement frameworks in the Americas to cost containment imperatives in Asia-Pacific. Navigating these nuances requires localized strategies underpinned by deep domain expertise.


The strategic recommendations presented throughout this summary provide a clear roadmap for optimizing portfolio management, strengthening supply chain resilience, and engaging payers with evidence-based value propositions. By integrating clinical innovation with commercial rigor, organizations can turn emerging challenges into opportunities for sustained growth and patient impact.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Indication
    • Diabetic Macular Edema
    • Diabetic Retinopathy
    • Retinal Vein Occlusion
    • Wet Age Related Macular Degeneration
  • Product
    • Aflibercept
    • Bevacizumab
    • Brolucizumab
    • Ranibizumab
  • Type
    • Biosimilar
    • Branded
  • End Use
    • Ambulatory Surgical Center
    • Hospital Ophthalmology Clinic
    • Specialty Eye Hospital
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Dosage Form
    • Prefilled Syringe
    • Vial

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan

This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Biogen Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Coherus BioSciences, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of faricimab as a dual VEGF-A and angiopoietin-2 inhibitor driving next-gen AMD therapy choices
5.2. Acceleration of biosimilar ranibizumab approvals spurring price competition in emerging ophthalmic markets
5.3. Adoption of sustained-release intravitreal implants reducing injection frequency burden for chronic AMD patients
5.4. Integration of AI-enabled OCT imaging tools optimizing individualized anti-VEGF dosing regimens
5.5. Development of topical nanoemulsion formulations aiming to replace intravitreal injections in diabetic macular edema
5.6. Expansion of real-world evidence studies validating extended dosing intervals to improve patient compliance
5.7. Regulatory frameworks evolving to streamline biosimilar interchangeability and market access pathways
5.8. Initiatives targeting rural and underserved populations to enhance anti-VEGF treatment accessibility in developing regions
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by Indication
8.1. Introduction
8.2. Diabetic Macular Edema
8.3. Diabetic Retinopathy
8.4. Retinal Vein Occlusion
8.5. Wet Age Related Macular Degeneration
9. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by Product
9.1. Introduction
9.2. Aflibercept
9.3. Bevacizumab
9.4. Brolucizumab
9.5. Ranibizumab
10. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by Type
10.1. Introduction
10.2. Biosimilar
10.3. Branded
11. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by End Use
11.1. Introduction
11.2. Ambulatory Surgical Center
11.3. Hospital Ophthalmology Clinic
11.4. Specialty Eye Hospital
12. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by Dosage Form
13.1. Introduction
13.2. Prefilled Syringe
13.3. Vial
14. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Regeneron Pharmaceuticals, Inc.
17.3.2. Bayer AG
17.3.3. F. Hoffmann-La Roche Ltd
17.3.4. Novartis AG
17.3.5. Biogen Inc.
17.3.6. Samsung Bioepis Co., Ltd.
17.3.7. Sandoz International GmbH
17.3.8. Coherus BioSciences, Inc.
18. Research AI19. Research Statistics20. Research Contacts21. Research Articles22. Appendix
List of Figures
FIGURE 1. MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET: RESEARCHAI
FIGURE 28. MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY WET AGE RELATED MACULAR DEGENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY WET AGE RELATED MACULAR DEGENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY HOSPITAL OPHTHALMOLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY HOSPITAL OPHTHALMOLOGY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY SPECIALTY EYE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY SPECIALTY EYE HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 85. CANADA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. CANADA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. CANADA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 88. CANADA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 89. CANADA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 90. CANADA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 91. CANADA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 92. CANADA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 93. CANADA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. CANADA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. CANADA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 96. CANADA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 97. MEXICO MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. MEXICO MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. MEXICO MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 100. MEXICO MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 101. MEXICO MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 102. MEXICO MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 103. MEXICO MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 104. MEXICO MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 105. MEXICO MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. MEXICO MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. MEXICO MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 108. MEXICO MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 159. GERMANY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. GERMANY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. GERMANY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 162. GERMANY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 163. GERMANY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 164. GERMANY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 165. GERMANY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 166. GERMANY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 167. GERMANY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. GERMANY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. GERMANY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 170. GERMANY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 171. FRANCE MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 172. FRANCE MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 173. FRANCE MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 174. FRANCE MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 175. FRANCE MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 176. FRANCE MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 177. FRANCE MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 178. FRANCE MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 179. FRANCE MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. FRANCE MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. FRANCE MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 182. FRANCE MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 195. ITALY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 196. ITALY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 197. ITALY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 198. ITALY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 199. ITALY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 200. ITALY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 201. ITALY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 202. ITALY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 203. ITALY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. ITALY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. ITALY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 206. ITALY MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 207. SPAIN MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. SPAIN MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. SPAIN MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 210. SPAIN MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 211. SPAIN MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 212. SPAIN MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 213. SPAIN MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 214. SPAIN MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 215. SPAIN MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. SPAIN MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. SPAIN MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 218. SPAIN MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 255. DENMARK MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. DENMARK MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. DENMARK MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 258. DENMARK MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 259. DENMARK MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 260. DENMARK MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 261. DENMARK MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 262. DENMARK MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 263. DENMARK MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. DENMARK MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. DENMARK MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 266. DENMARK MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS MONOCLONAL ANTIBODY ANTI-VE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market report include:
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Biogen Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Coherus BioSciences, Inc.

Related Topics

Related Reports

Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2025 - Product Image

Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 90 Pages
  • Global
From
Anti-VEGF Therapy for Cancer Market by Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer), Drug Class (Monoclonal Antibodies, Tyrosine Kinase Inhibitors), Therapy Line, Administration Route, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Anti-VEGF Therapy for Cancer Market by Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer), Drug Class (Monoclonal Antibodies, Tyrosine Kinase Inhibitors), Therapy Line, Administration Route, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Retinal Vein Occlusion - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Retinal Vein Occlusion - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 174 Pages
  • Global
From
Wet Age-Related Macular Degeneration (Wet-AMD)- Pipeline Insight, 2025 - Product Image

Wet Age-Related Macular Degeneration (Wet-AMD)- Pipeline Insight, 2025

  • Clinical Trials
  • 280 Pages
  • Global
From
Macular Degeneration Pipeline Analysis Report - Product Image

Macular Degeneration Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.